Takeda – International Tradition in the Capital Region

The history of the pharmaceutical company Takeda from Japan has been 239 years, for 39 years

Takeda is active in Germany. During this time it has acquired and developed the current locations in Berlin, Oranienburg, Konstanz and Singen. In…

3 Min
More

Rare Diseases in the Capital Region: an Overview of Activities and Challenges

The development of drugs for the treatment of rare diseases is difficult, as is the development of safe methods of diagnosis. Although the number of patients suffering from rare diseases is relatively large, the estimated 8,000 different rare…

3 Min
More

How the German Capital Region is evolving during Sars-Cov-2

 

In late January the Sars-Cov-2 pandemic officially arrived and started spreading across Germany. Since then – like in almost every other country globally - every new day feels completely new, uncertain and presents previously unknown challenges,…

4 Min
More

Interview: Caroline Schmutte, Head of the Wellcome Trust foundation office in Berlin

 

At the beginning of 2019, the British foundation Wellcome Trust opened an office in Berlin, thus expanding its activities to Germany. The first project funded by the foundation in Germany is a translation partnership with the Berlin Institute of…

3 Min
More

„Just like Cambridge“ – the Boom of Biomedicine in Berlin

The pharmaceutical company Bayer wants to help turn Berlin into a biotech hub like Boston. This is possible, says head of research Stefan Oelrich in an interview with the Tagesspiegel.

5 Min
More

Myelo Therapeutics Awarded NIH-NIAID Contract Valued up to $6 Million over 3 Years for Development of Myelo001 as Treatment for Acute Radiation Syndrome

Myelo Therapeutics GmbH, a clinical-stage pharmaceutical company focused on developing therapies for cancer supportive care and medical countermeasures (MCM), announced that it has been awarded a 3-year development contract valued at up to $6…

3 Min
More

Unexpectedly potent protein droplets – Berlin researchers discover new pathomechanism of hereditary diseases

Repeats of individual building blocks within proteins are the cause of many hereditary diseases, but how such repeats actually cause disease is still largely unknown. Researchers in Berlin investigated how repeat elongations lead to the disease…

4 Min
More

NOXXON PROVIDES UPDATE ON CLINICAL TRIAL RECRUITMENT AND CORPORATE OPERATIONS DURING COVID-19 PANDEMIC

NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), provided a corporate update on its measures in response to the potential impact of…

2 Min
More

Launching the COVID-19 manufacturing fund

Opening a fund to help to ensure vital parts for COVID-19 related projects are manufactured.

2 Min
More

Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX radiotherapy

Debiopharm, a Swiss-based biopharmaceutical company announced having entered into a worldwide, exclusive license & research agreement with 3B Pharmaceuticals (3BP), a German biotechnology firm, to further the development of their radioligand program,…

3 Min
More
Show more items